Placeholder Banner

BIO Comments on FDA Draft Guidance on CMC Postapproval Manufacturing Changes for Specified Biological Products

October 10, 2017

BIO submitted comments on the Food and Drug Administration’s (FDA) draft guidance, Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes for Specified Biological Products to Be Documented in Annual Reports.

BIO appreciates the effort to categorize listed annual reportable changes for biologics based on the associated commensurate risk, along with the annual reportable manufacturing type examples in the draft guidance.

However, BIO recommends the final guidance include examples of situations where annual reportable listed changes may be better categorized by applicants as a supplement based on certain specific circumstances. BIO asks for additional clarifications to the draft guidance, including whether this draft guidance will be aligned with the final ICH Q12 guideline.

Download Full Comments Below
2017-10-10 BIO Comments On CMC Postapproval In Annual Reports FINAL
Read full comment letter below
Discover More
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the U.S. Senate Committee on Health, Education, Labor, and Pensions’ (Committee’s) Request for Information on Improving and Protecting Access to Gene Therapies…
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Department of Health and Human Services’ (HHS’) proposed Notice of Benefit and Payment Parameters (NBPP) for 2025.
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Centers for Medicare & Medicaid Services’ Draft CY 2025 Part D Redesign Program Instructions.